MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of…Read More
Avenue Therapeutics Announces First Patient Dosed in Phase 1b2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy Kennedys Disease
